NEW YORK (GenomeWeb News) – Biosearch Technologies today announced it has acquired the exclusive worldwide rights to the turboFISH technology.
As a result, the Petaluma, Calif.-based firm maintains exclusive access to continuing Stellaris RNA FISH-based inventions from Rutgers University, it said.
TurboFish is a method for rapid single molecule RNA FISH. In a statement, Marc Beal, director of corporate development and licensing at Biosearch, said, "Point-of-care, point-of-contact, hospital bedside, and immediate care facilities are now target markets for real-time gene expression analysis using turboFISH. Extending turboFISH into the [operating room] for intraoperative analysis may allow for real-time cancer diagnostics, eliminating the need, ambiguities, and procedure of formalin fixation and paraffin embedding tissues for days-later analysis."
Financial and other terms of the deal were not disclosed.
Biosearch recently acquired a majority stake in LightSpeed Genomics. The two firms are co-developing a gene expression platform, optimized to work on Stellaris RNA FISH assays for detecting and quantifying single molecular RNA targets within individual cells.